Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

Part of paid clinical trials in Orange, California.

Sponsor
University of California, Irvine
Study ID
NCT06221800
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Microbiome — DIAGNOSTIC_TEST
    Stool and saliva samples will be collected

Study Details

This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.

Key Dates

Start date
Jan 31, 2024
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
82 participants (estimated)

Arms

  • Arm: Treatment with PD1/L1 monotherapy
  • Arm: Treatment with PD1/L1 + chemotherapy
  • Arm: Treatment with Tyrosine Kinase Inhibitor

Primary Outcome Measure

Gut microbiomes in advanced/metastatic NSCLC patients [ Time Frame: Up to 2 years ]

Central Contacts

  • Chao Family Comprehensive Cancer Center University of California, Irvine
    1-877-827-8839
    [email protected]
  • University of California Irvine Medical

Locations (1)

FacilityCityStateZIPSite coordinators
Chao Family Comprehensive Cancer Center University of California, IrvineOrangeCalifornia92868
Misako Nagasaka, MD, PhD
[email protected]
877-827-8839

Find similar trials in Orange, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Chao Family Comprehensive Cancer Center University of California, Irvine· Orange, CA

Related Studies